With tight research budgets becoming the norm, Raybiotech is confident that the Risk-Free Trial program will attract the attention of life scientists. “The outstanding quality of our ELISA kits is increasingly recognized by the research community, and we are honored to have so many investigators rely on our product,” says Rani Huang, vice president of Raybiotech. “Our ELISA sales have been rapidly increasing over the last several years. With this risk-free policy, we intend to build on that momentum.” Raybiotech began selling ELISA kits seven years ago, and currently offers a selection of over 500 competitively priced kits, with a focus on human, mouse, rat and porcine cytokines and signaling molecules.
The risk-free trial will be offered to all U.S. customers, applicable to any single ELISA or EIA kit. For more information, visit this link: http://www.raybiotech.com/risk_free_trial.asp
ABOUT RAYBIOTECH
RayBiotech, Inc., introduced the first commercially available cytokine antibody array in 2001, and began selling ELISA kits in 2004. Since then, RayBiotech products have been featured in hundreds of publications, including top-tier journals, such as Nature, Nature Medicine, Cell, Lancet, PNAS (USA) and many others. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
CONTACT:
Brett Burkholder
Dir. Marketing & Business Development
RayBiotech, Inc.
Ph: +1-770-729-2992, 1-888-494-8555 (US & Canada)
Email: info@raybiotech.com
Web: http://www.RayBiotech.com